Clinical Trial Results: SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease [Phase 2]

View source ↗

Summary

Phase 2 trial results for SENS-401 aiming to prevent cisplatin-induced ototoxicity in adults with cancer have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hearing Loss
• Ototoxicity

Drugs mentioned

• SENS-401

Snippet

Sponsor: Sensorion | Conditions: Hearing Loss Ototoxic | Phase 2 | Status: COMPLETED | Results posted: 2026-07-02